Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of mRNA-1283 versus mRNA-1273 for prevention of COVID-19 in participants aged ≥12 years
2023-000884-30Phase 3
- Sponsor
- Moderna Inc
- Start
- Mar 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of mNEXSPIKE and elasomeran in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Moderna Inc. Primary endpoint: Part 1: Geometric Mean Ratio (GMR) of Omicron BA.4/5 neutralizing antibody titers for mRNA-1283.222 versus mRNA-1273.222.
02
Drugs
mNEXSPIKEelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2023-000884-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-000884-30.